Zealand Pharma A/S (ZEAL.CO)
| Previous close | 938.50 |
| Open | 945.00 |
| Bid | 945.50 x 0 |
| Ask | 949.50 x 0 |
| Day's range | 937.50 - 970.00 |
| 52-week range | 212.20 - 970.00 |
| Volume | |
| Avg. volume | 330,154 |
| Market cap | 67.046B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Yahoo Finance Video
Existing home sales, a day with Fed's Susan Collins: Catalysts
It's Friday, so the market (^DJI, ^IXIC, ^GSPC) is working extra hard for the weekend. Catalysts Hosts Madison Mills and Brad Smith crunch the numbers on the latest economic data — June's Purchasing Managers' Index (PMI) and May's US existing home sales — and explore the biggest themes driving equities. National Association of Realtors (NAR) Chief Economist Lawrence Yun drops in to weigh in on the existing home sales print and the relationship between mortgage rates and the Federal Reserve's monetary policy. JPMorgan Asset Management Global Market Strategist Jack Manley also explores market trends tied back to the market's interest rate sentiments. Lastly, Yahoo Finance's own Jennifer Schonberger spent a day with Federal Reserve Bank of Boston President and CEO Susan Collins, shadowing the Fed officials as she met with business owners and community leaders. Catch the full exclusive interview with Collins here. This post was written by Luke Carberry Mogan.
- Barrons.com
Zealand Pharma's Weight Loss Drug Performs Well in Early Trials
Zealand Pharma's petrelintide shot has the potential to reduce body weight by more than 15% in longer trials, analysts from Jefferies write in a note following data from a 16-week trial that showed an 8.6% average weight loss. Results from the trial show petrelintide supports potential weight loss to a degree which is at least on par with GLP-1 medications that decrease appetite, such as Ozempic, but with an improved tolerability profile. The initial trial data also shows petrelintide could lead to higher quality and more sustainable weight loss through lean mass preservation, the analysts added.
